According to filings with the U.S. Securities and Exchange Commission, Solstice Health has raised $21 Million in new Series A funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

Investors in the company’s current round of funding include: Transformation Capital, Twelve Below, Virtue Ventures

About Solstice Health
Solstice is the AI-native marketing agency for pharma brands. The company pairs AI technology with in-house experts to generate, review and activate compliant marketing content at speed, replacing the traditional handoffs between agencies, regulatory teams and in-house marketers. Headquartered in New York, Solstice is backed by leading investors including Transformation Capital, Twelve Below, Virtue Ventures, Ford Street Ventures, Go Global Ventures, Cory Capital and others.

To learn more, visit https://www.solsticehealth.co/
Linkedin: https://www.linkedin.com/company/solsticehealth/

Contact:
Aris Saxena, Chief Executive Officer
https://www.linkedin.com/in/aris-saxena-a82808149/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.